NYSEAMERICAN:MTNB

Matinas BioPharma - MTNB Stock Forecast, Price & News

$0.43

+0.02 (+4.84%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.42
▼
$0.44
50-Day Range: N/A
52-Week Range: $0.39
▼
$1.00

Volume: 363,241 shs
Average Volume: 271,848 shs
Market Capitalization: $94.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Institutional Ownership

Headlines

Short Interest

Social Media

Matinas BioPharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 592.8% Upside
$3.00 Price Target
Short Interest: Healthy
0.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.11) to ($0.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Matinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Matinas BioPharma has a forecasted upside of 592.8% from its current price of $0.43.
Amount of Analyst Coverage
Matinas BioPharma has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.52% of the outstanding shares of Matinas BioPharma have been sold short.
Short Interest Ratio / Days to Cover
Matinas BioPharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Matinas BioPharma has recently decreased by 26.80%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Matinas BioPharma does not currently pay a dividend.
Dividend Growth
Matinas BioPharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MTNB.

3.3

News and Social Media Coverage

News Sentiment
Matinas BioPharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Matinas BioPharma this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for MTNB on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Matinas BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.20% of the stock of Matinas BioPharma is held by insiders.
Percentage Held by Institutions
Only 12.84% of the stock of Matinas BioPharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Matinas BioPharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Matinas BioPharma is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Matinas BioPharma is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Matinas BioPharma has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

March 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and MoonLake Immunotherapeutics (MLTX)

March 19, 2023 | finanznachrichten.de

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

March 28, 2023 | Investing Daily (Ad)

A 100% Win Rate In 2022…

The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you.

March 18, 2023 | seekingalpha.com

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript

March 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Spruce Biosciences (SPRB)

March 16, 2023 | finance.yahoo.com

Q4 2022 Matinas BioPharma Holdings Inc Earnings Call

March 15, 2023 | finance.yahoo.com

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

March 14, 2023 | msn.com

Earnings Outlook For Matinas BioPharma Hldgs

March 28, 2023 | Investor Place Media (Ad)

The "King Of Quants" sees 10X potential...

Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...

March 8, 2023 | finance.yahoo.com

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

March 2, 2023 | finance.yahoo.com

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

February 23, 2023 | seekingalpha.com

MTNB Matinas BioPharma Holdings, Inc.

January 31, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Matinas BioPharma (MTNB)

January 30, 2023 | finance.yahoo.com

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

January 23, 2023 | finance.yahoo.com

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

January 20, 2023 | finance.yahoo.com

12 Hot Penny Stocks On the Rise

January 14, 2023 | seekingalpha.com

Matinas stock rises on team up with National Resilience for drug delivery technology

January 12, 2023 | finance.yahoo.com

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

November 2, 2022 | seekingalpha.com

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript

November 2, 2022 | finance.yahoo.com

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

October 27, 2022 | finance.yahoo.com

Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022

October 24, 2022 | finance.yahoo.com

Deadly Fungi Are Infecting More Americans

October 21, 2022 | seekingalpha.com

Matinas BioPharma says mid-stage study for meningitis therapy met main goal

October 21, 2022 | finance.yahoo.com

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

October 21, 2022 | finance.yahoo.com

Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

October 19, 2022 | finance.yahoo.com

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

October 12, 2022 | finance.yahoo.com

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Company Calendar

Last Earnings: 11/07/2021
Today: 3/28/2023
Next Earnings (Estimated): 5/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:MTNB
CUSIP: N/A
CIK: N/A
Web: www.matinasbiopharma.com
Phone: (908) 484-8805
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +592.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,000,000.00
Net Margins: N/A
Pretax Margin: -658.63%
Return on Equity: -50.66%
Return on Assets: -41.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.06
Quick Ratio: 8.06

Sales & Book Value

Annual Sales: $3.19 million
Price / Sales: 29.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 2.55

Miscellaneous

Outstanding Shares: 217,260,000
Free Float: 197,277,000
Market Cap: $94.07 million
Optionable: Not Optionable
Beta: 2.09

Key Executives

Jerome D. Jabbour
President, Chief Executive Officer & Director

Keith A. Kucinski
Chief Financial Officer

Raphael J. Mannino
Chief Scientific Officer & Senior Vice President

James J. Ferguson
Chief Medical Officer

Hui Liu
Chief Technology Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MTNB Stock - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings or view top-rated stocks.
What is Matinas BioPharma's stock price forecast for 2023?: 2 Wall Street analysts have issued 12 month price objectives for Matinas BioPharma's stock. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 592.8% from the stock's current price.
View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts.
How have MTNB shares performed in 2023?: Matinas BioPharma's stock was trading at $0.5563 on January 1st, 2023. Since then, MTNB shares have decreased by 22.2% and is now trading at $0.4330.
View the best growth stocks for 2023 here.
Are investors shorting Matinas BioPharma?: Matinas BioPharma saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,120,000 shares, a decline of 26.8% from the February 28th total of 1,530,000 shares. Based on an average daily trading volume, of 312,900 shares, the short-interest ratio is presently 3.6 days.
View Matinas BioPharma's Short Interest.
When is Matinas BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our MTNB earnings forecast.
How were Matinas BioPharma's earnings last quarter?: Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings results on Sunday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.01.

What other stocks do shareholders of Matinas BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).
What is Matinas BioPharma's stock symbol?: Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
Who are Matinas BioPharma's major shareholders?: Matinas BioPharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (2.02%), Geode Capital Management LLC (0.83%), Millennium Management LLC (0.11%), Jane Street Group LLC (0.09%), Private Advisor Group LLC (0.09%) and Virtu Financial LLC (0.07%). Insiders that own company stock include Adam K Stern and Patrick G Lepore.
View institutional ownership trends.
How do I buy shares of Matinas BioPharma?: Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Matinas BioPharma's stock price today?: One share of MTNB stock can currently be purchased for approximately $0.43.
How much money does Matinas BioPharma make?: Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $94.07 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.
How can I contact Matinas BioPharma?: Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Matinas BioPharma - MTNB Stock Forecast, Price & News

Matinas BioPharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

MTNB Stock News Headlines

MTNB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

MTNB Stock - Frequently Asked Questions

Overall MarketRank^™